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Abstract
Background: Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to
regimens not containing PI are scarce.
Methods: Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or
to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing
CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the
CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the
frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after the
switch, and last visit). Finally, we explored whether the CD4+ counts evolved differently in patients who switched
to NNRTI or NRTI-only regimens by considering: the overall CD4+ trends, the time to CD4+≥ 500/mm3 after the
switch, and the area-under-the-curve (AUC) of the CD4+ after the switch.
Results: Eight hundred and ninety-six patients, followed for a median of 2,121 days, were included. At TPLR,
hinges occurred in 581/844 (68.9%), but in only 40/581 (6.9%) within a time interval (180 days) compatible with a
possible relationship to the switch; furthermore, in 19/40 cases, CD4+ counts appeared to decrease after the
hinges. In comparison with the NNRTI group, the NRTI group showed CD4+ count greater at baseline (P = 0.0234)
and before the switch (P ≤ 0.0001), superior CD4+ T-cell increases after HAART was started, lower probability of not
achieving CD4+ ≥ 500/mm3 (P = 0.0024), and, finally, no significant differences in the CD4+ T-cell AUC after the
switch after adjusting for possible confounders (propensity score and pre-switch AUC). Persistence at CD4+ < 200/
mm3 was observed in 34/435 (7.5%) patients, and a decrease below this level was found in only 10/259 (3.9%) with
baseline CD4+ ≥ 350/mm3.
Conclusions: Switching from first-line PI to NNRTI- or NRTI-based regimens did not seem to impair CD4+ trend
over long-term follow-up. Although the greater CD4+ increases in patients who switched to the NRTI-only regimen
was due to higher CD4+ counts before the switch, several statistical analyses consistently showed that switching to
this regimen did not damage the ongoing immune-reconstitution. Lastly, the observation that CD4+ T-cell counts
remained low or decreased in the long term despite virological success merits further investigation.
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Background
The introduction of protease inhibitors (PI) as part of
highly active antiretroviral therapy (HAART) in 1996
improved the clinical outcome of HIV-infected patients,
decreased mortality rates by 3 to 10-fold and trans-
formed HIV into a chronic disease [1]. The clinical ben-
efits obtained by HAART (either for AIDS or non-AIDS
related illnesses) were strongly correlated with CD4+
recovery [2,3].
Several studies demonstrated a positive effect of PI on
CD4+ recovery over short-term follow-up [4-8], espe-
cially boosted by ritonavir [9,10]. The anti-apoptotic
properties of PIs are thought to be the explanation for
the better CD4+ responses [11]. Although other studies
have failed to confirm this effect [12-15], it is important
to assess whether simplification from PI-including to
PI-sparing regimens may influence immune-recovery
over long-term follow-up. Such studies are worth pursu-
ing because treatment simplification is the most
frequent reason for switching treatment in current clini-
cal practice. Moreover, adverse events, intolerance and
inconvenience of PI-containing regimens have led physi-
cians to change an effective PI-based HAART to less
complex and better-tolerated regimens [16].
Data on CD4+ evolution after switching PI have been
limited by short follow-up and small numbers of
patients [5,17-22]. Moreover, the patients were either
experienced or naïve to antiretroviral drugs before
HAART initiation [22], leading to conclusions not
immediately applicable to a well defined population.
In planning a treatment simplification strategy, low
cost and preservation of all the remaining classes
(should HIV drug resistance eventually emerge) are two
important benefits of switching to nucleoside reverse-
transcriptase inhibitor (NRTI)-only regimens. In treat-
ment simplification, the risk of virological failures,
demonstrated with regimens containing only NRTI as
first-line [23], has been limited to patients who have
experienced previous virological failures and have accu-
mulated HIV resistance to this class [17,18].
Therefore, the aim of the present study was to charac-
terize the patterns of CD4+ responses in HIV-infected
patients receiving virologically effective HAART regimens
who changed from PI to regimens not containing PI: spe-
cifically, NNRTI or NRTI-only regimens. We evaluated
whether this switch modified the ongoing evolutionary
pattern of CD4+ T-cell count over long-term follow-up.
Methods
Design of the study
Retrospective inter-cohort study in patients achieving
HIV-RNA < 500 copies/ml after 12 months of a first
antiretroviral regimen including PI.
Study patients
We followed 896 patients (median 2,121 days: IQR:
1,463-2,593) from MASTER, ICONA, Chelsea & West-
minster, S. Raffaele and Modena HIV cohort databases,
who initiated antiretroviral therapy with 2NRTI+PI
(boosted or not by ritonavir) between 1997 to 2006. Fol-
low-up was censored at loss to follow-up, death, two
consecutive HIV-RNA≥ 500 copies/ml, or treatment dis-
continuation, whichever occurred first. The chosen
threshold for viral suppression was HIV-RNA < 500
copies/ml since ultra-sensitive assays were not available
throughout the study period.
Patients were grouped according to treatment change:
671 patients switched to non-NRTI (NNRTI)-based
therapy (NNRTI group); 225 patients switched to NRTI-
only (NRTI group).
The study was approved by the ethics committees of
each participating center and the written consent was
obtained from the participants.
Influence of the switch on the ongoing trend of the CD4+
T-cell count
In order to provide reliable estimates, we evaluated
patients with ≥ 10 CD4+ determinations. A two-phase
linear regression [24] was fitted on the natural logarithm
of the CD4+ count to assess the presence of a change in
the ongoing CD4+ trend (hinge) and its possible relation-
ship to the time of the switch. If a two-phase model did
not fit better than simple linear regression (P > 0.10, con-
servatively), it was possible to conclude that no change in
the CD4-trend had occurred; otherwise, we assessed
whether the hinge occurred before, or ≤ 180 days after,
the therapy switch (as a sensible time-lag for a cause-
effect relationship), or later. The two-phase regression
slope after the hinge, corresponding to at least 1 CD4+
T-cell/mm3/day decrease or increase, was considered to
express a decreasing or an increasing trend, respectively.
Overall trends of CD4+ T-cell count in patients who
switched to NNRTI or NRTI-only regimens (unadjusted
comparisons)
First, to compare CD4+ trends, we described the overall
CD4-patterns across four relevant time-points (baseline,
before the switch, immediately after and at the last visit)
together with their percentage changes from baseline
and the evolution of the frequencies in four CD4+
classes (≤ 200, 201-350, 351-500, and > 500/mm3). As a
per-patient analysis, we recorded the frequencies of
stable, decreasing or increasing patterns at the above
four time-points, considering, for simplicity, the three
classes: CD4+ ≤ 200, 201-350, and > 350/mm3.
Second, the Kaplan-Meier estimate of the cumulative
probability of not obtaining CD4+ ≥ 500/mm3 in at
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least two sequential determinations after HAART was
calculated. The follow-up time of the patients with base-
line CD4+ < 500/mm3 was truncated at 1,460 days when
20% of the enrolled patients were still observed.
Third, a flexible nonparametric mixed-effects model
(FNMEM) was applied taking individualization into
account according to Liang [25]. A reference band of
two standard errors width was calculated, centered at
the average of the two estimated curves for the NNRTI
and NRTI groups. If the two curves were not encapsu-
lated in this reference band, they were considered,
roughly, to be statistically different. Because the data
were too sparse at the end of the treatment, data were
cut at 2258 days when 30% of the enrolled patients were
still under observation. Software R implementing the
function LME [26], and Matlab© [27] were used.
Comparison of the CD4+ T-cell counts after the switch in
patients who switched to NNRTI or NRTI-only regimens
(adjusted comparisons)
We calculated the area under the curve (AUC) of the
CD4-counts (log-transformed), adjusted for time
(divided by the days of follow-up) as a summary statistic
of the overall amount of CD4+ at each time point. In
particular, we derived: (i) the pre-switch AUC from
before the start of therapy (median 14 days, interquartile
range, IQR: 0-36 days) to the therapy switch, and (ii) the
post-switch AUC from the first CD4-count immediately
after the switch (median 95 days, IQR: 63-126 days)
until the last observation.
To compare non-randomized groups, the propensity
score of belonging to the NNRTI or NRTI group was
calculated using a multiple logistic model [28]. The
effect of the switch on the post-switch AUC was tested
by ANCOVA (NNRTI group vs. NRTI group) with, as
covariates, the propensity score and the pre-switch AUC
to adjust for differences in the CD4+ T-cell count before
the switch or by the Wilcoxon rank-sum test for unad-
justed comparisons. Qualitative variables were compared
with a c2 test.
Owing to the large sample size of at least 225 patients,
it was possible to demonstrate a very low effect size of
about 0.25 (a difference of 25% in the variability of the
phenomenon investigated), which could be clinically
insignificant.
Statistical analyses were performed using SAS©
version 9.1.
Results
Patients’ characteristics at baseline
Regarding the baseline characteristics of the 896 patients
(Table 1), no statistically significant differences were
found between the two groups except for calendar year
at study initiation and CD4+ counts.
In fact, more patients in the NRTI group initiated
HAART in the period 2001-2003 than patients in the
NNRTI group. Moreover, there was a statistically signifi-
cant difference between the CD4+ counts in favour of
the NRTI group (P = 0.0234) at baseline. This difference
was also apparent for the CD4+ classes, though at a bor-
derline significance level (P = 0.0782). Also, the CD4+
AUC before the switch was significantly greater (P <
0.0001) in the NRTI group (mean ± standard deviation,
SD: 499 ± 263.9 cells/mm3 per day) than in the NNRTI
group (418 ± 236.6 cells/mm3 per day).
Table 1 Characteristics of patients at baseline
Qualitative variable - N (%) NNRTI group
N = 671
NRTI group
N = 225
P
Gender [Male] 536 (79.9%) 182 (80.9%) 0.7429
Risk factor for HIV acquisition 0.6749
IVDU 148 (22.1%) 46 (20.4%)
Homo-bisexual 198 (29.5%) 65 (28.4%)
Heterosexual 254 (37.9%) 83 (36.9%)
Other 16 (2.4%) 9 (4%)
Unknown 55 (8.2%) 22 (9.8%)
Nationality 0.6511
Europe or North America 608 (90.6%) 208 (92.4%)
Other 41 12
Unknown 22 5
HCV-Ab 0.8498
Positive 169 (25.2%) 55 (24.5%)
Negative 432 (64.4%) 149 (66.2%)
Unknown 70 (10.4%) 21 (9.3%)
CDC ‘93 Class C 200 (29.8%) 64 (28.4%) 0.6982
CD4+ classes 0.0782
≥ 200/mm3 342 (51.0%) 93 (41.3%)
201-350/mm3 146 (21.8%) 56 (24.9%)
351-500/mm3 101 (15.0%) 45 (20.0%)
> 500/mm3 82 (12.2%) 31 (13.8%)
Centre 0.1448
Master 399 (59.5%) 115 (51.1%)
Chelsea & Westminster 97 (14.5%) 38 (16.9%)
ICONA 139 (20.7%) 60 (26.7%)
HSR+Modena 35 (5.3%) 12 (5.3%)
Calendar year at study initiation 0.0137
1997-2000 264 (39.3%) 70 (31.1%)
2001-2003 309 (46.1%) 129 (57.3%)
2004-2006 98 (14.6%) 26 (11.6%)
Boosted-PI as first line 78 (11.6%) 30 (13.3%) 0.4957
Quantitative variables
Mean (SD) age [years] 39 (35-45) 38 (34-44) 0.3680
Mean (SD) pre-treatment
HIV-RNA [log10 copies/ml]
5.012
(4.415-5.430)
5.000
(4.511-5.519)
0.6269
Median (IQR) CD4-count
[cells/mm3]
196 (86-377) 249 (103-403) 0.0234
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Regarding specific drugs that could influence CD4+
count [29,30], zidovudine was prescribed in 501/896
(55.92%) patients, tenofovir in only 8 patients, while the
association of tenofovir/didanosine was never prescribed.
Boosted PI as first line regimens were prescribed in 108/
896 (12.05%) patients. No statistical differences in the
prescription of these drugs were found between the two
groups.
Influence of the switch on the ongoing trend of the CD4+
T-cell count
Patients in the group 1 were switched to regimens con-
taining either efavirenz (373/671 = 55.59%) or nevira-
pine (298/671 = 44.41%). Zidovudine was prescribed in
350/671 (52.16%) patients, tenofovir in 44/671 (6.56%)
and the association of tenofovir/didanosine in 15/671
(2.23%). Regarding the group 2, zidovudine was pre-
scribed in 186/225 (82.67%) patients (P < 0.0001 vs.
group 1), tenofovir in 18/225 (8%) and the association
of tenofovir/didanosine in only 2 patients.
Among 844/896 (94.2%) patients with ≥ 10 CD4+
determinations, a two-phase linear regression model
fitted better (P < 0.10) than a simple linear regression in
436/627 (69.5%) patients in the NNRTI group and in
145/217 (66.8%) in the NRTI group. The hinges
occurred at medians of 617 days (IQR: 336-1041) and
737 days (IQR: 392-1223) before the therapy switch and
at medians of 308 days (IQR: 135-579) and 404 days
(IQR: 218-722) after HAART initiation in the NNRTI
and in the NRTI group, respectively.
Table 2 shows the percentages of patients with
increasing, stationary or decreasing trends after the
hinge, stratified by the time of its relationship with the
switch: before, ≤ 180 days or >180 days. Estimates of
the trends are also shown. Overall in the two groups,
the hinges occurred within 180 days after the switches
in only 40/581 (6.9%) patients, and the CD4-counts
appeared to decrease after the hinges in only 19/40
(47.5%). Thus, the switches did not appear to be related
to decreasing CD4+ trends in 93.1% of the cases. In
addition, decreasing CD4+ trends occurred in 122
(22.5%) patients out of the 541 with hinges before (N =
65) or more than 180 days after (N = 57) the switch.
Overall trends of CD4+ T-cell count in patients who
switched to NNRTI or NRTI-only regimens (unadjusted
comparisons)
Medians, percentage increases and strata of CD4-count
during the study are shown in Table 3. Estimates were
based on medians of 21 (IQR: 14-27) and 21 (IQR:
15-27) CD4+ determinations per patient in the NNRTI
and in the NRTI group, respectively. CD4-counts
increased by at least double the baseline, especially from
baseline to the period immediately after the switch,
while smaller increases occurred afterwards. Also, the
CD4+ AUC before the switch was significantly greater
(P < 0.0001) in the NRTI group (mean ± SD: 499 ±
263.9 cells/mm3 per day) than in the NNRTI group (418
± 236.6 cells/mm3 per day), as well as the CD4+ count
before the switch (P < 0.0001).
Of note, the percentage of patients with CD4+ ≤ 200/
mm3 was always about 5%. Among patients with base-
line CD4-count ≤ 200/mm3, a transition to upper CD4+
strata occurred in 316/342 (92.4%) and 85/93 (91.3%) in
the NNRTI and in the NRTI group, respectively.
Among patients with baseline CD4+ count between 201
and 350/mm3, 126/146 (86.3%) in the NNRTI group and
53/56 (94.64%) in the NRTI group had an increase to
upper CD4+ strata, while two (1.37%) in the NNRTI
group and two (3.57%) in the NRTI group had a decrease
to ≤ 200 CD4+/mm3. Lastly, a decrease to CD4+ T-cell
count ≤ 350/mm3 was found in 7/183 (3.8%) and 3/76
(3.95%) patients with baseline CD4+ T-cell count > 350/
mm3 in the NNRTI group and in the NRTI group,
respectively.
Survival probabilities for not obtaining CD4+ ≥ 500/
mm3 in at least two sequential determinations after
HAART are depicted in Figure 1. In 637 patients with
baseline CD4+ < 500/mm3 followed for a median of 943
(IQR: 505-1619, but truncated to 1460) days, the prob-
ability of not achieving a confirmed CD4-count ≥ 500/
mm3 was higher in the NNRTI group than in the NRTI
group (Log-Rank = 9.2309; df = 1; P: 0.0024). In particu-
lar, at one year it was 0.85 (95%CI = 0.81-0.89) vs. 0.79
(0.73-0.85), and at three years 0.54 (0.50-0.58) vs. 0.38
(0.30-0.46).
Regarding FNMEM, the two population curves of the
CD4+ increase after the commencement of HAART to
the last observation for the NNRTI group and the NRTI
group and the reference bands [25] are depicted in
Figure 2. The CD4+ increase appeared to be greater in
the NRTI group than in the NNRTI group.
Comparison of the CD4+ T-cell counts after the switch in
patients who switched to NNRTI or NRTI-only regimens
(adjusted comparisons)
There was a statistically significant difference in the
CD4+ counts (Table 3) in favour of the NRTI group
immediately after the switch and at the last observation
(P < 0.0001); this difference was also consistently
observed for the CD4+ classes (P = 0.0073, and P =
0.0044, respectively).
Furthermore, the CD4+ AUC was significantly greater
(P < 0.0001) in the NRTI group (mean ± SD: 661 ± 300.0
cells/mm3 per day) than in the NNRTI group (574 ±
266.5 cells/mm3 per day). However, the change in the
CD4+ AUC (difference between before and after the
switch) proved statistically insignificant (P = 0.0586:
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NNRTI group increase of 155.6 ± 132.8 cells/mm3 per
day; and NRTI group increase of 162.3 ± 134.7 cells/mm3
per day).
Discussion
We followed a cohort of antiretroviral-naïve patients
initiating HAART containing PI over a long term-
follow-up of 2,121 days (median) under virologically
effective regimens, switching to regimens not including
PI. Linear regression analysis seemed to rule out the
possibility that switching from PI to alternative regimens
caused immune damage. In fact, in 31.2% of patients, no
hinges could be detected, while among those who pre-
sented a hinge, its relationship to the switch was reliable
(≤ 180 days) in only 6.9% (40/581) patients. Moreover, a
decreasing trend was demonstrated in only half (19/40).
While the CD4+ T-cell count increased more in patients
who were switched to NRTI-only regimens than in
those who were switched to NRTI+NNRTI, this was
probably because, in the NRTI group, the CD4+ T-cell
Table 2 Characteristics of the hinges in the trends of CD4+ T-cell counts (two-phase linear regression model)
NNRTI group N = 436/627 (69.4%) NRTI group N = 145/217 (66.8%)
Time of the hinge relative to the switch (categories)
Before the switch ≤ 180 days from the
switch
>180 days from the
switch
Before the switch ≤ 180 days from the
switch
>180 days from the
switch
N = 325/436
(74.5%)
N = 31/436 (7.1%) N = 80/436 (18.3%) N = 118/145
(81.4%)
N = 9/145 (6.2%) N = 18/145 (12.4%)
Increasing CD4+ trend after the hinge relative to the pre-switch trend (categories)
N = 210/325
(64.6%)
N = 7/31 (22.6%) N = 18/80 (18.7%) N = 68/145
(46.9%)
N = 3/9 (33.3%) N = 1/18 (5.5%)
Estimates of the increasing trend (median CD4+/mm3/day, IQR or min-max*/individual$ values where indicated)
1.0003 1.0003 1.0005 1.0003 *min-max:
1.0002 to 1.0005 1.0002 to 1.0082 1.0001 to 1.0015 1.0002 to 1.0004 1.0001 to 1.00025 $1.0001
Stationary CD4+ trend after the hinge relative to the pre-switch trend (categories)
N = 68/325
(20.9%)
N = 8/31 (25.8%) N = 20/80 (25%) N = 32/145
(22.1%)
N = 3/9 (33.3%) N = 5/18 (27.8%)
Decreasing CD4+ trend after the hinge relative to the pre-switch trend (categories)
N = 47/325
(14.5%)
N = 16/31 (51.6%) N = 45/80 (56.2%) N = 18/145
(12.4%)
N = 3/9 (33.3%)
N = 12/18 (66.7%)
Estimates of the decreasing trend (median CD4+/mm3/day, IQR or min-max* values where indicated)
-1.0002 -0.99981 -1.0007 -1.0003 *min-max: -1.0004
-1.0001 to -1.0004 -0.99959 to -0.999945 -1.0029 to 1.0003 -1.0005 to -1.0002 -0.99585 to -0.99988 -1.0015 to -1.0003
Table 3 CD4+ T-cell counts at relevant time points of the study
Pre-switch Post-switch Last observation
NNRTI
group
NRTI
group
NNRTI
group
NRTI
group
NNRTI
group
NRTI
group
Median (IQR): days from HAART 788
(489-1200)
1002
(646-1432)
896
(595-1331)
1103
(759-1620)
2080
(1398-2567)
2220
(1638-2663)
Median (IQR) CD4-count [cells/mm3]* 468
(321-660)
561
(402-758)
478
(322-683)
568
(386-799)
538
(389-742)
634
(446-871)
CD4+ increase (%) from baseline 138.8 125.3 143.9 128.1 174.5 154.6
N (%) CD4+ classes$
≤200/mm3 61
(9.1%)
10
(4.5%)
44
(6.6%)
12
(5.3%)
30
(4.5%)
10
(4.4%)
201-350/mm3 140
(20.9%)
36
(16.0%)
147
(21.9%)
33
(14.7%)
92
(13.7%)
26
(11.6%)
351-500/mm3 167
(24.9%)
48
(21.3)
165
(24.6%)
45
(20.0%)
168
(25.0%)
33
(14.7%)
>500/mm3 303
(45.1%)
131
(58.2%)
315
(46.9%)
135
(60.0%)
381
(56.8%)
156
(69.3%)
*Comparisons at Pre-switch: P < 0.0001; Post-switch: < 0.0001; Last observation: < 0.0001.
$Comparisons at Pre-switch: P < 0.0038; Post-switch: < 0.0073; Last observation: < 0.0044.
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count at baseline was higher and CD4+ T-cell count
increase before the switch was greater. In fact,
ANCOVA models adjusted both for the propensity
score and for pre-switch AUC demonstrated no signifi-
cant differences in the post-switch AUC.
Regarding the main object of this paper (the evalua-
tion of the influence of the switch on CD4+ trend) our
results are consistent with the meta-analysis by Bucher
et al. [31] on simplification studies over a maximum
follow-up of 52 weeks and with that of Le Moing et al.
[22] who conducted an observational study over a med-
ian follow-up of 57 months, demonstrating a non-detri-
mental effect of switching from PI to NNRTI (229
patients) or NRTI-only (34 patients). However, our
study is based on many more patients (896) who
switched, and over a longer follow-up (median of about
72 months). More recently, Elzi et al. [32] demonstrated
that switch “per se” was not associated with a increased
risk of virological failure. Moreover, no difference in the
median CD4+ count increase at 12 months was noted
among switchers and individuals who did not change
their treatment [32]. The present study adds data
regarding CD4+ increase over a longer follow-up, and
about a certain class regimen: the fact that the compari-
son of CD4+ changes between the two groups from
before to after the switch proved statistically insignifi-
cant allows us to conclude that the ongoing increase of
CD4+ T-cells was not significantly influenced by the
switch to the first (NNRTI) or to the second (NRTI)
regimen under study.
Other studies assessed CD4+ increases upon initia-
tion of antiretroviral therapy indicating that CD4+
increases were better with PI (especially boosted by
ritonavir) compared with NNRTI or triple NRTI regi-
mens even though virological responses were similar
among the three regimens or better with NNRTI than
with PI boosted by ritonavir [4-10]. Our analysis per-
formed in patients who already attained undetectable
HIV-RNA and maintained it for quite a long time did
not suggest that abandoning PI was able to influence
the ongoing trend in CD4+ count. It could be that the
protective effect of PIs (probably mediated by anti-
apoptotic mechanisms [11]) is more important when
the immune system is more hyper-activated or
damaged for the presence of actively replicating HIV
(as it happens in antiretroviral naïve patients off treat-
ment) than when the immune system has already been
restored (at least in part) through the HIV control
induced by HAART.
Regarding the second objective (description of the
long-term CD4+ counts), we found a plateau in CD4+
increase emerging from year 4 after HAART initiation.
This evidence confirms previous results showing that
the increase in CD4+T-cell count after HAART had a
steep initial phase, followed by a second phase during
which the increase was slower but continuing in patients
who maintained HIV-RNA <1,000 copies/ml [22,33-35],
or reached a plateau after a variable number of years
[36-38]. Furthermore, considering the individual pattern,
the CD4+T-cell slopes started to decrease in several
cases even before a plateau in the overall population
was reached. In fact, linear regression analysis demon-
strated that several patients presented a decreasing
Figure 1 Proportion of patients not having CD4+ ≥ 500/mm3
at each time point (the NNRTI group is represented with the
black line and the NRTI group is represented with the red line).
Legend to figure 1: Time (days) is represented on the x-axis,
truncated at 1,460 days when 20% of the study patients were still
observed.
Figure 2 Population curves for group features and the
reference band (shaded area) for the NNRTI group
(represented with the continuous red line) and for the NRTI
group (represented with the dotted blue line). Legend to figure
2: The figure represents the scatter plot of the logarithm of the CD4
+ count (LCD4, y-axis) against time for the two groups under study.
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pattern from a median of approximately one year after
initiation of treatment.
Decreasing CD4+ patterns could be due either to the
exhaustion of the regenerative capacity of the immune
system (favored by persistent immune activation despite
virological suppression in the peripheral blood compart-
ment), or to the fact that <500 HIV-RNA copies/ml as a
cut-off could have covered incomplete viral suppression.
While we await a demonstration that low-level viral
replication, assessed by ultrasensitive assays, affects the
regenerative capacity of the immune system, strict mon-
itoring of CD4-count must be recommended even in
those with long-term virological control. Moreover, we
should experiment with interventions to slow or reverse
unfavorable CD4+ trends and we should address
whether eventual CD4+ decrease impacts on the virolo-
gical and clinical outcomes of therapy.
From a clinical point of view, our results may provoke
some considerations. First, we confirmed, using a large
cohort over a long follow-up, that switching form PI-
regimens to regimens not containing PI is a viable strat-
egy since immune-reconstitution is not compromised.
Importantly, although we did not assess clinical out-
comes or quality of life, CD4+ increase has been corre-
lated with improvement in both measures [39].
Regarding the type of regimen to which patients were
switched, long-term evolution of CD4+ count did not
appear to be impaired by the use of NRTI-only combi-
nations that, owing to their suboptimal virological effi-
cacy, have been progressively abandoned even for
simplification as initial treatment of previously naive
patients [23]. By contrast, in treatment simplification,
the risk of virological failure to NRTI is mostly
restricted to patients who have previously failed [17,18].
Moreover, all the other classes of antiretroviral drugs
remain available should NRTI regimens eventually fail
and HIV resistance to this class emerges. Regarding
toxicity, recognized adverse events of some NRTI (e.g.,
anaemia due to zidovudine, or lipoatrophy due to
dideoxynucleosides) were a further incentive to abandon
these regimens. However, alternative regimens may pro-
voke adverse events as well (e.g., neuro-psychological
effects due to efavirenz). Furthermore, NRTI-only regi-
mens are cheaper than the others: for instance, in Italy,
the cost of treating 100 patients with co-formulated
NRTI for 1 year is 998,796 Euro in comparison to
1,441,800 Euro for co-formulated NRTI+NNRTI, with a
saving in direct costs of 443,004 per year). In view of
these considerations, we suggest that NRTI-regimens
should be re-considered for use in treatment simplifica-
tion strategies, especially in resource-limited settings
where other recommended options are not readily avail-
able. Obviously, this conclusion is based merely on the
consideration of CD4+ count in presence of sustained
undetectable HIV RNA as it was the focus in this retro-
spective analysis. Other important aspects were not
assessed, such as adverse events, quality of life, the risk
of virological failure after a switch and subsequent evo-
lution of CD4+ count.
This work has limitations that need to be considered.
The first limitation is that it was not a randomized clini-
cal trial in which patients were randomized to continue
PI or switch to alternative regimens. For example, it is
possible that patients whose CD4+ counts did not
increase as expected were either not switched or
switched to regimens containing NNRTI but not to
NRTI-only. However, we limited this bias by excluding
from the study patients who continued on PI since their
characteristics were too unbalanced compared with the
other two groups, especially for CD4+ trend during the
follow-up. Notwithstanding the exclusion of this group,
a selection bias could have occurred favoring, in particu-
lar, the NRTI group. For this reason, we conducted sev-
eral analyses to overcome the unbalance between the
groups, even adjusting for propensity score and CD4+
count preceding the switch, all pointing to the fact that
the switch and the choice of one regimen or the other
did not impair the ongoing immune-reconstitution in
our patients. The second limitation is that, by definition,
all patients with virological failure were excluded from
the study. Should patients in the NRTI group had failed
more frequently, they would have been favored in this
analysis. The third limitation is that, as discussed above,
we used the 500 copies/ml cut-off as indicative of unde-
tectable HIV RNA and this could have masked immune
damage exerted by low-level viral load. However, ultra-
sensitive tests were not available for most patients at the
time of the study and there is still a lack of data indicat-
ing that immune-reconstitution is different among
patients with lower levels of plasma HIV load. The
fourth limitation is that we did not focus on specific
drugs, since we were interested in treatment strategy
and consideration of multiple drugs would have reduced
the power of the study to a significant extent.
Conclusions
In conclusion, switching from first-line PI-containing
regimens to NNRTI or NRTI-based regimens in the pre-
sence of <500 copies/ml HIV RNA did not appear to
damage the CD4+ trend that was ongoing before the
switch. Moreover, as far as long-term immunological
outcome is concerned, we suggest that NRTI-only regi-
mens be further evaluated for use in selected patients
who are responding (and did not fail before) to other
regimens. Lastly, we tried to provide unbiased results
notwithstanding the observational nature of the study by
analyzing the data from several aspects using pertinent
statistical approaches. However, it is still possible that
Torti et al. BMC Infectious Diseases 2011, 11:23
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our results reflect a best case scenario regarding CD4+
immune recovery, especially in patients switched to
NRTI-only. Since alternative drugs and classes are avail-
able and, for some of them, a beneficial effect on CD4+
reconstitution has been hypothesized (e.g. CCR5 co-
receptor inhibitors [40]), our approach could be applied
in observational studies on novel strategies using these
compounds. However, possible biases intrinsic in such
observational analyses are difficult to avoid. Therefore,
randomized controlled trials remain the best way to
study this aspect.
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